Hedge Funds Have Never Been This Bullish On The Home Depot, Inc. (HD)

Trump Is Warned on Security Risk in Infineon’s Cypress Deal

(Bloomberg) -- U.S. national security officials are recommending that President Donald Trump block Infineon Technologies AG’s proposed acquisition of Cypress Semiconductor Corp., according to people familiar with the matter.The officials are concerned that Infineon’s $8.7 billion deal for the American chipmaker poses a risk to national security, said three people familiar with the matter. Infineon, a German semiconductor maker with substantial Chinese revenue, has tried to negotiate an agreement with the government that would let the takeover proceed, but hasn’t been able to reach a deal, one of the people said. All of the people asked not to be named discussing a national security matter.It wasn’t clear why officials with the Committee on Foreign Investment in the U.S., which reviews foreign takeovers of U.S. businesses, see a national security risk from the deal. The panel, however, is particularly sensitive to any transaction that could allow Chinese buyers to get their hands...

Investors Withdraw Most Cash From U.S. Credit Funds in a Decade

(Bloomberg) -- Investors withdrew $12.2 billion from U.S. funds that buy corporate bonds and loans, the biggest weekly total in at least a decade, as the spreading coronavirus battered markets globally.High-grade bond funds saw $4.8 billion of outflows in the week ended March 4, according to Refinitiv Lipper. Junk-bond funds had $5.1 billion withdrawn, while leveraged loan investors pulled $2.29 billion during the period. The outflows represented the largest combined total in data compiled by Bloomberg going back to January 2010. Investors have pulled back from credit as worries intensify that the spreading virus will slash economic growth and crimp corporate cash flows. A widely followed derivatives index that measures risk in U.S. credit markets has surged in the past two weeks as investors rushed to hedge against losses. The market turmoil shut the U.S. investment-grade bond market for six straight days before reopening this week, and lending in the junk-bond...

Inovio Pharmaceuticals’ vaccine for coronavirus could be ready by year’s end

Since news of the coronavirus outbreak emerged, in contrast to the sell-off in the broader market, companies associated with the COVID-19 space have seen valuations significantly increase.This week, the baton was handed over to Inovio Pharmaceuticals (INO). Shares of the infectious disease warrior have shot up nearly 130% this week, following the announcement of development timelines for its COVID-19 vaccine (INO-4800) using its DNA vaccine platform.Inovio’s COVID-19 vaccine, INO-4800, was developed in just 3 hours once the COVID-19 sequence was deposited in data banks for public access. This, according to Maxim’s Jason McCarthy, is testament to the company’s ability to react speedily and efficiently to an emergency situation.Inovio is a regular recipient of grants for the development of infectious disease vaccines. CEPI (the Coalition for Epidemic Preparedness Innovations), awarded Inovio a $9 million grant in February to advance development of a COVID-19 vaccine. This is on top of previous grants Inovio...